| Literature DB >> 36016138 |
Gavin George1,2, Michael Strauss1, Emma Lansdell1, Nisha Nadesan-Reddy3, Nomfundo Moroe4, Tarylee Reddy5, Ingrid Eshun-Wilsonova6, Mosa Moshabela3.
Abstract
COVID-19 vaccine hesitancy poses a threat to the success of vaccination programmes currently being implemented. Concerns regarding vaccine effectiveness and vaccine-related adverse events are potential barriers to vaccination; however, it remains unclear whether tailored messaging and vaccination programmes can influence uptake. Understanding the preferences of key groups, including students, could guide the implementation of youth-targeted COVID-19 vaccination programmes, ensuring optimal uptake. This study examined university staff and students' perspectives, preferences, and drivers of hesitancy regarding COVID-19 vaccines. A multi-methods approach was used-an online convenience sample survey and discrete choice experiment (DCE)-targeting staff and students at the University of KwaZulu-Natal, South Africa. The survey and DCE were available for staff and students, and data were collected from 18 November to 24 December 2021. The survey captured demographic characteristics as well as attitudes and perspectives of COVID-19 and available vaccines using modified Likert rating questions adapted from previously used tools. The DCE was embedded within the survey tool and varied critical COVID-19 vaccine programme characteristics to calculate relative utilities (preferences) and determine trade-offs. A total of 1836 staff and students participated in the study (541 staff, 1262 students, 33 undisclosed). A total of 1145 (62%) respondents reported that they had been vaccinated against COVID-19. Vaccination against COVID-19 was less prevalent among students compared with staff (79% of staff vs. 57% of students). The vaccine's effectiveness (22%), and its safety (21%), ranked as the two dominant reasons for not getting vaccinated. These concerns were also evident from the DCE, with staff and students being significantly influenced by vaccine effectiveness, with participants preferring highly effective vaccines (90% effective) as compared with those listed as being 70% or 50% effective (β = -3.72, 95% CI = -4.39 to -3.04); this characteristic had the strongest effect on preferences of any attribute. The frequency of vaccination doses was also found to have a significant effect on preferences with participants deriving less utility from choice alternatives requiring two initial vaccine doses compared with one dose (β = -1.00, 95% CI = -1.42 to -0.58) or annual boosters compared with none (β = -2.35, 95% CI = -2.85 to -1.86). Notably, an incentive of ZAR 350 (USD 23.28) did have a positive utility (β = 1.14, 95% CI = 0.76 to 1.53) as compared with no incentive. Given the slow take-up of vaccination among youth in South Africa, this study offers valuable insights into the factors that drive hesitancy among this population. Concerns have been raised around the safety and effectiveness of vaccines, although there remains a predilection for efficient services. Respondents were not enthusiastic about the prospect of having to take boosters, and this has played out in the roll-out data. Financial incentives may increase both the uptake of the initial dose of vaccines and see a more favourable response to subsequent boosters. Universities should consider tailored messaging regarding vaccine effectiveness and facilitate access to vaccines, to align services with the stated preferences of staff and students.Entities:
Keywords: South Africa; discrete choice experiment; vaccine hesitancy; youth
Year: 2022 PMID: 36016138 PMCID: PMC9412872 DOI: 10.3390/vaccines10081250
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Discrete choice experiment attributes and levels.
| Attribute | Definition | Attribute Levels |
|---|---|---|
|
| Location/venues where vaccine services are provided | Government–local clinic or hospital, mobile clinics |
| Private hospital, family doctor, or pharmacy | ||
| At a UKZN vaccination site | ||
|
| Length of time taken to complete the vaccination process | 1 h |
| 3 h | ||
| 5 h | ||
|
| An amount provided as reward for getting vaccinated | No fee or incentive |
| ZAR 50 (USD 3.33) | ||
| ZAR 350 (USD 23.28) | ||
|
| Percentage reduction in serious disease cases in a vaccinated group of people | Very effective (90%) |
| Moderately Effective (70%) | ||
| Partially Effective (50%) | ||
|
| Country/Region where the vaccine was developed | USA/North America |
| UK/Europe | ||
| Russia | ||
| China | ||
|
| Number of vaccine shots required in order to complete the regimen | One dose |
| Two doses | ||
|
| Frequency of additional vaccine booster shots required | One vaccination provides life-long immunity (no boosters) |
| A booster required every 5 years | ||
| Annual booster vaccinations required |
ZAR 1 = USD 0.0665007: https://www.xe.com/currencyconverter/convert/?Amount=50&From=ZAR&To=USD (accessed on 23 February 2022).
Sociodemographic characteristics of respondents by UKZN association.
| Characteristic Measures | Staff ( | Students ( | Prefer Not to Answer ( | |
|---|---|---|---|---|
|
| Male | 188 (34.8%) | 438 (34.7%) | 13 (39.4%) |
| Female | 351 (64.9%) | 812 (64.3%) | 14 (42.4%) | |
| Other | 1 (0.2%) | 5 (0.4%) | 1 (3%) | |
| Prefer not to answer | 1 (0.2%) | 7 (0.6%) | 5 (15.2%) | |
|
| <35 years | 106 (19.6%) | 1140 (90.3%) | 15 (45.5%) |
| 35–49 years | 230 (42.5%) | 104 (8.2%) | 9 (27.3%) | |
| 50 years or older | 204 (37.7%) | 14 (1.1%) | 5 (15.2%) | |
| Prefer not to answer | 1 (0.2%) | 4 (0.3%) | 4 (12.1%) | |
|
| African | 215 (39.7%) | 969 (76.8%) | 16 (48.5%) |
| Coloured | 26 (4.8%) | 25 (1.9%) | 0 | |
| Indian | 131 (24.2%) | 210 (16.6%) | 3 (9.1%) | |
| White | 137 (25.3%) | 28 (2.2%) | 7 (21.2%) | |
| Other | 6 (1.1%) | 9 (0.7%) | 1 (3%) | |
| Prefer not to answer | 26 (4.8%) | 21 (1.7%) | 6 (18.2%) | |
|
| South African | 495 (91.5%) | 1,176 (93.2%) | 24 (72.7%) |
| Non-South African | 44 (8.1%) | 78 (6.2%) | 3 (9.1%) | |
| Prefer not to answer | 2 (0.4%) | 8 (0.6%) | 6 (18.2%) | |
Prior COVID-19 testing and vaccination among respondents.
| Characteristic Measures | Have You Ever Tested Positive for COVID-19? | Have You Been Vaccinated for COVID-19? | |||||
|---|---|---|---|---|---|---|---|
| Yes | No | Prefer Not to Answer | Yes | No | Prefer Not to Answer | ||
|
| Staff | 80 (16.4%) | 403 (82.8%) | 4 (0.8%) | 429 (79.3%) | 94 (17.4%) | 17 (3.1%) |
| Student | 126 (11.9%) | 923 (86.8%) | 14 (1.3%) | 716 (56.7%) | 455 (36.1%) | 71 (5.6%) | |
| Prefer not to answer | 1 (3.6%) | 27 (96.4%) | 0 | 18 (54.6%) | 6 (18.2%) | 7 (21.2%) | |
|
| Male | 69 (12.5%) | 476 (86.2%) | 7 (1.3%) | 385 (60.3%) | 208 (32.6%) | 36 (5.6%) |
| Female | 137 (13.6%) | 862 (85.4%) | 11 (1.1%) | 767 (65.2%) | 343 (29.1%) | 55 (4.7%) | |
| Other | 0 | 6 (100%) | 0 | 4 (57.1%) | 2 (28.6%) | 1 (14.3%) | |
| Prefer not to answer | 1 (10%) | 9 (90%) | 0 | 7 (53.9%) | 2 (15.4%) | 3 (23.1%) | |
|
| <35 years | 119 (11.2%) | 928 (87.6%) | 13 (1.2%) | 708 (56.2%) | 458 (36.3%) | 78 (6.2%) |
| 35-49 years | 59 (18.9%) | 251 (80.2%) | 3 (100%) | 250 (72.9%) | 77 (22.5%) | 11 (3.2%) | |
| 50 years or older | 29 (14.5%) | 170 (85%) | 1 (0.5%) | 202 (90.6%) | 18 (8.1%) | 3 (1.4%) | |
| Prefer not to answer | 0 | 4 (80%) | 1 (2%) | 3 (33.3%) | 2 (22.2%) | 3 (33.3%) | |
COVID-19 perspectives.
| COVID-19 Perspective | M | SD |
| ||
|---|---|---|---|---|---|
|
| Staff | 3.28 | 1.14 | 0.157 | −0.05 |
| Student | 3.18 | 1.17 | |||
|
| Staff | 3.78 | 0.92 | 0.139 | −0.17 |
| Student | 3.69 | 1.04 | |||
|
| Staff | 3.63 | 1.15 | 0.256 | 0.08 |
| Student | 3.55 | 1.27 | |||
|
| Staff | 2.29 | 0.96 | 0.008 * | 0.08 |
| Student | 2.14 | 0.97 | |||
|
| Staff | 3.20 | 1.16 | 0.286 | 0.06 |
| Student | 3.27 | 1.19 | |||
|
| Staff | 3.66 | 1.08 | 0.001 * | 0.15 |
| Student | 3.84 | 1.04 | |||
|
| Staff | 4.40 | 0.97 | 0.010 * | −0.14 |
| Student | 4.52 | 0.82 | |||
|
| Staff | 4.04 | 1.08 | 0.433 | −0.04 |
| Student | 4.09 | 1.11 | |||
* p < 0.05.
COVID-19 vaccine attitudes.
| COVID-19 Vaccine Attitude | Mean | SD |
| ||
|---|---|---|---|---|---|
|
| Staff | 4.04 | 1.20 | 0.001 * | 0.20 |
| Student | 3.79 | 1.19 | |||
|
| Staff | 3.90 | 1.11 | 0.001 * | 0.28 |
| Student | 3.58 | 1.10 | |||
|
| Staff | 3.70 | 1.11 | 0.001 * | 0.17 |
| Student | 3.51 | 1.07 | |||
|
| Staff | 2.67 | 0.97 | 0.237 | 0.06 |
| Student | 2.60 | 0.97 | |||
|
| Staff | 2.67 | 1.09 | 0.002 * | −0.17 |
| Student | 2.85 | 1.04 | |||
|
| Staff | 3.28 | 1.12 | 0.593 | −0.02 |
| Student | 3.31 | 1.09 | |||
|
| Staff | 4.05 | 1.18 | 0.001 * | 0.17 |
| Student | 3.84 | 1.18 | |||
|
| Staff | 4.04 | 1.00 | 0.295 | 0.05 |
| Student | 3.98 | 1.01 | |||
|
| Staff | 3.14 | 1.26 | 0.001 * | −0.46 |
| Student | 3.69 | 1.13 | |||
|
| Staff | 3.02 | 1.45 | 0.001 * | −0.66 |
| Student | 3.91 | 1.28 | |||
* indicates significance.
Figure 1Main effects mixed effects logit model results—mean relative utility estimates and standard deviations. Notes: The point estimates show the mean relative utility (or beta coefficients) for each attribute level, and the error bars show the 95% confidence interval for each attribute level, relative to the baseline level for each attribute (shown in brackets on the left). Positive utilities represent what participants prefer, and negative utilities represent what participants do not prefer. The table on the right-hand side of the figure shows the standard deviation coefficients and p-values, which indicates where preference heterogeneity exists within the sample. Significant p-values indicate significant heterogeneity, which should be further explored to understand more clearly why preferences diverge, and which key sample sub-groups have specific preferences for particular characteristics.